Reports Q3 revenue $0 vs. $366,000 last year. Revenue decrease is primarily related to completion of the wind down of the PUR1900 Phase 2b clinical trial during the year ended December 31, 2024. The company’s total cash and cash equivalents balance as of September 30 was $4.8M. The company anticipates that its cash position, based on current operational efficiencies and prioritization of spending, is sufficient to fund its operations into the fourth quarter of 2026.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PULM: